Eduardo Esteban Montalvo-Jave
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Eduardo Esteban Montalvo-Jave has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Allan Tsung
Department of Surgery, University of Virginia, Charlottesville, Virginia, USA
1 shared publication - Felipe Boff Maegawa
Division of General & GI Surgery, Department of Surgery, Emory University, Atlanta, GA
1 shared publication - Francisco Tustumi
Department of Health Sciences, Hospital Israelita Albert Einstein, São Paulo, Brazil
1 shared publication - Georgios Tsoulfas
Department of Transplant Surgery, Center for Research and Innovation in Solid Organ Transplantation, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
1 shared publication - Giovanna Mennitti Shimoda
Faculdade de Ciencias Médicas da Santa Casa de São Paulo, Brazil
1 shared publication - José L. Herrera-Ojeda
Traslational Research Unit, Medica Sur Clinic & Foundation, Mexico City, Mexico
1 shared publication
Latest Publications
- Open Access
- 27 June 2025
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 48 (10) , 2279-2293
The pathophysiological link between type 1 diabetes and MASLD: insights into insulin resistance and liver dysfunction
Type 1 Diabetes Mellitus (T1DM) is an autoimmune disorder characterized by the destruction of pancreatic β-cells, leading to significant endogenous insulin deficiency. In this context, inflammation plays a crucial role in the pathogenesis of the disease. Traditionally, insulin resistance has been associated with Type 2 Diabetes Mellitus (T2DM); however, recent studies have shown that it also occurs in a significant proportion of T1DM patients. Regarding the prevalence of Non-Alcoholic Fatty Liver Disease associated with metabolic dysfunction (MASLD), variations are observed depending on the studied population and diagnostic method used, although there has been a global increase in this condition in T1DM patients. MASLD is closely linked to insulin resistance, both hepatic and peripheral, suggesting that MASLD progression is associated with worsening insulin resistance. The relationship between both pathologies is bidirectional, as the presence of one can accelerate the progression of the other. When both coexist, the natural history of both diseases is altered, increasing the risk of complications and worsening patient prognosis.
- 27 June 2025
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 48 (10) , 2279-2293
Open AccessThe pathophysiological link between type 1 diabetes and MASLD: insights into insulin resistance and liver dysfunction
Type 1 Diabetes Mellitus (T1DM) is an autoimmune disorder characterized by the destruction of pancreatic β-cells, leading to significant endogenous insulin deficiency. In this context, inflammation plays a crucial role in the pathogenesis of the disease. Traditionally, insulin resistance has been associated with Type 2 Diabetes Mellitus (T2DM); however, recent studies have shown that it also occurs in a significant proportion of T1DM patients. Regarding the prevalence of Non-Alcoholic Fatty Liver Disease associated with metabolic dysfunction (MASLD), variations are observed depending on the studied population and diagnostic method used, although there has been a global increase in this condition in T1DM patients. MASLD is closely linked to insulin resistance, both hepatic and peripheral, suggesting that MASLD progression is associated with worsening insulin resistance. The relationship between both pathologies is bidirectional, as the presence of one can accelerate the progression of the other. When both coexist, the natural history of both diseases is altered, increasing the risk of complications and worsening patient prognosis.
- Open Access
- 1 January 2025
- Published by FapUNIFESP (SciELO) in ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo)
- Vol. 38, e1908
Global strategies for the diffusion of robotic surgery
Background: The global adoption of robotic surgery has advanced rapidly in high-income countries, yet its diffusion remains limited in resource-constrained settings due to financial, infrastructural, and educational barriers. As surgical technology evolves, there is an urgent need to promote countries’ equitable access to robotic platforms worldwide. Aims: The aim of this study was to analyze global strategies employed to promote the diffusion of robotic surgery, with a particular focus on overcoming barriers in resource-limited settings, and to provide practical insights that can guide its equitable and sustainable implementation. Methods: This study is a multinational, policy-oriented integrative review conducted under the guidance of the Research Committee of the Society for Surgery of the Alimentary Tract in the USA (SSAT). The study integrates a bibliometric analysis, a literature review, and expert insights from diverse healthcare environments. Contributions were gathered from SSAT members. Results: Robotic platforms are predominantly concentrated in North America, Western Europe, and Eastern Asia, with the USA hosting nearly 60% of all installations. Research output is similarly skewed, with few countries and institutions producing most clinical trials. Key barriers to diffusion include high costs, lack of infrastructure, limited training capacity, regulatory hurdles, and resistance among surgeons. Facilitators include public–private partnerships, philanthropic support, technology transfer, simulation platforms, and curriculum integration by professional societies. Conclusions: Achieving global equity in robotic surgery requires coordinated action across research, education, clinical practice, policy, and infrastructure. Global cooperation and innovation in implementation strategies can help bridge the current disparities and promote safe, cost-effective surgical care in underserved regions, improving patient outcomes.
- 1 January 2025
- Published by FapUNIFESP (SciELO) in ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo)
- Vol. 38, e1908
Open AccessGlobal strategies for the diffusion of robotic surgery
Background: The global adoption of robotic surgery has advanced rapidly in high-income countries, yet its diffusion remains limited in resource-constrained settings due to financial, infrastructural, and educational barriers. As surgical technology evolves, there is an urgent need to promote countries’ equitable access to robotic platforms worldwide. Aims: The aim of this study was to analyze global strategies employed to promote the diffusion of robotic surgery, with a particular focus on overcoming barriers in resource-limited settings, and to provide practical insights that can guide its equitable and sustainable implementation. Methods: This study is a multinational, policy-oriented integrative review conducted under the guidance of the Research Committee of the Society for Surgery of the Alimentary Tract in the USA (SSAT). The study integrates a bibliometric analysis, a literature review, and expert insights from diverse healthcare environments. Contributions were gathered from SSAT members. Results: Robotic platforms are predominantly concentrated in North America, Western Europe, and Eastern Asia, with the USA hosting nearly 60% of all installations. Research output is similarly skewed, with few countries and institutions producing most clinical trials. Key barriers to diffusion include high costs, lack of infrastructure, limited training capacity, regulatory hurdles, and resistance among surgeons. Facilitators include public–private partnerships, philanthropic support, technology transfer, simulation platforms, and curriculum integration by professional societies. Conclusions: Achieving global equity in robotic surgery requires coordinated action across research, education, clinical practice, policy, and infrastructure. Global cooperation and innovation in implementation strategies can help bridge the current disparities and promote safe, cost-effective surgical care in underserved regions, improving patient outcomes.